ADMA Biologics reports second quarter 2026 results as ASCENIV revenue climbs 24%

ADMA Biologics reported second quarter 2026 results on August 5, 2026, with total revenue for the quarter ended June 30, 2026 of $124.4 million, compared to $122.0 million for the quarter ended June 30, 2025¹. ASCENIV revenue was $102.9 million, up 24% year-over-year, while BIVIGAM revenue was $19.4 million, a 49% decline year-over-year, though it grew sequentially from first quarter 2026 trough levels.¹

On the pipeline, the company said SG-001 development remains on track, with ADMA continuing to advance plasma collection optimization, potency assay development and preclinical activities supporting planned conformance lot production during the second half of 2026, ahead of the anticipated submission of its pre-Investigational New Drug meeting package to the FDA by year-end.¹ The company describes SG-001 as a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia.¹

ADMA also highlighted new clinical evidence for ASCENIV. It said it submitted an abstract for the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting highlighting results from a real-world analysis of 127 medically complex primary immunodeficiency patients, most of whom had previously received other immune globulin therapies, showing statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following ASCENIV initiation.¹

The company reiterated FY2026 guidance for total revenue of $530 million to $560 million, Adjusted Net Income of $170 million to $200 million, and Adjusted EBITDA of $265 million to $300 million¹. On capital return, ADMA said it remains active with share repurchases and is on track to complete its previously stated $200 million or more 2026 share repurchase target.¹ The balance sheet showed cash and cash equivalents of $136.0 million as of June 30, 2026, compared to $87.6 million at December 31, 2025.¹